Yes, denifanstat reduced moderate to severe acne in trials. It is not yet available by prescription in the United States.
Denifanstat is an investigational once-daily oral drug that blocks fatty acid synthase, or FASN. That enzyme helps drive new fat production in skin. The drug lowers sebum production and inflammation instead of killing bacteria like an antibiotic or unclogging pores like a retinoid.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does denifanstat work?
- How well did it work at 12 weeks?
- Do the results last to one year?
- Is it safe so far?
- Can you get denifanstat now?
How does denifanstat work?
Denifanstat targets oil production at its source. Less new fat means less sebum feeding clogged pores. Less sebum also means less inflammation around breakouts. That approach differs from most current acne pills. Oral antibiotics target bacteria and inflammation for short courses.
Isotretinoin shrinks oil glands but carries strict safety monitoring. Hormonal treatments only fit selected patients. Denifanstat is taken as a 50 mg pill once daily in the trials. It is a small-molecule drug, so it spreads through the body after swallowing. The goal is steadier oil control without an antibiotic effect.
How well did it work at 12 weeks?
In a 12-week Chinese Phase 3 trial with 480 moderate-to-severe acne patients, 33.2% reached treatment success on denifanstat 50 mg versus 14.6% on placebo, according to Managed Healthcare Executive denifanstat Phase 3 results. Success meant clear or almost clear skin with major improvement on the Investigator's Global Assessment. Lesion counts also fell more with treatment.
Total lesions fell 57.4% versus 35.4% with placebo, inflammatory lesions 63.5% versus 43.2%, and noninflammatory lesions 51.9% versus 28.9%, with improvement reported as early as week 4, according to Managed Healthcare Executive deeper 52-week acne results. That early change matters for daily life. Fewer red, painful bumps can mean less makeup, fewer spot treatments, and easier shaving. The placebo group also improved, which is common in acne trials with skin care and follow-up.
Do the results last to one year?
Patients who continued into a 40-week open-label extension reached 52 weeks of total treatment. Overall success rose to 56.7%, with 71.8% mean total-lesion reduction and 76.9% inflammatory-lesion reduction, according to Dermatology Times 52-week acne lesion reductions. Longer treatment appeared to deepen the benefit. Inflammatory breakouts improved more than total counts.
That pattern fits a drug that gradually lowers oil production. The year-long results have a key limit. All published efficacy comes from China, and the extension had no placebo group, so HCPLive notes U.S. effectiveness and head-to-head benefit against antibiotics or isotretinoin remain unproven sustained acne control report.
Is it safe so far?
Long-term tolerability looked favorable in the extension. There were no discontinuations for adverse events and no drug-related serious adverse events. The most common treatment-related events were dry skin at 7.1% and dry eye at 5.9%. All cases were mild or moderate.
That profile may appeal to readers who fear severe dryness, mood, or lab monitoring with stronger options. Still, trial safety is not full safety. Larger and more diverse groups can reveal rarer effects. Continued follow-up in the U.S. trial will add needed data.
Can you get denifanstat now?
No. Denifanstat remains investigational and is not FDA-approved for acne. Sagimet announced FDA clearance to start U.S.
testing in August 2026 and dosing of the first AURORA patient in October 2026, according to the company via GlobeNewswire first AURORA patient dosed. The AURORA trial plans about 800 patients age 12 and older, including about 450 adolescents. Participants receive denifanstat 50 mg or placebo at a 2:1 ratio for 12 weeks, followed by a 40-week extension to support a future drug application. Readers who want to act now can take these steps:.
- Keep using the current prescribed routine and track breakouts, oiliness, and irritation.
- Ask a dermatologist whether a clinical trial site near you is enrolling ages 12 and older.
- Bring a list of past antibiotics, retinoids, hormonal treatments, and isotretinoin use to that visit.
- Do not order supposed denifanstat online, since approved product does not exist.